Propylthiouracil for alcoholic liver disease.

Area of Science:

• Hepatology
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• Alcoholic liver disease (ALD) encompasses a spectrum of conditions, including steatosis, fibrosis, hepatitis, and cirrhosis.
• The efficacy of propylthiouracil (PTU) in managing ALD remains a subject of clinical investigation.

Purpose of the Study:

• To systematically evaluate the beneficial and harmful effects of propylthiouracil in patients diagnosed with alcoholic liver disease.
• To synthesize evidence from randomized clinical trials regarding PTU's impact on mortality and disease progression in ALD.

Main Methods:

• A comprehensive search of multiple electronic databases (Cochrane Hepato-Biliary Group, CENTRAL, MEDLINE, EMBASE, Science Citation Index Expanded) was conducted up to April 2011.
• Included were randomized clinical trials of patients with various stages of ALD, comparing propylthiouracil to placebo or no intervention, regardless of blinding or publication status.
• Data analysis followed the intention-to-treat method, with rigorous evaluation of bias risk across domains including allocation concealment, blinding, and reporting.

Main Results:

• Analysis of six randomized clinical trials involving 710 patients indicated no significant difference in all-cause mortality (RR 0.93, 95% CI 0.66-1.30) or liver-related mortality (RR 0.90, 95% CI 0.58-1.40) between PTU and placebo groups.
• Propylthiouracil did not demonstrate significant effects on liver disease complications or histological improvements.
• While not linked to a significant increase in non-serious adverse events, PTU use was associated with occasional serious adverse events, including leukopenia and generalized bullous eruption.

Conclusions:

• Current evidence does not support the use of propylthiouracil for treating alcoholic liver disease, as it showed no significant benefits in mortality or liver complications.
• The available studies had a high risk of bias, characterized by wide confidence intervals, suggesting potential for random and systematic errors.
• There is insufficient evidence to recommend propylthiouracil for alcoholic liver disease outside the context of well-designed randomized clinical trials.